Literature DB >> 8634782

Clonal analysis of colorectal tumors using K-ras and p53 gene mutations as markers.

B R Dix1, P D Robbins, D V Spagnolo, G L Padovan, A K House, B J Iacopetta.   

Abstract

Mutations to the K-ras oncogene and p53 tumor suppressor gene are two of the most common genetic lesions in human cancers. In the present study we examined the clonality of colorectal tumors with respect to each of these genetic alterations. Screening for mutations was carried out using the polymerase chain reaction-based technique of single-strand conformation polymorphism. Eleven primary colorectal adenocarcinomas and two secondary adenocarcinomas were analyzed at four different sites within the tumor. Involved pericolic lymph nodes were collected from nine of these cases, a metastatic deposit in the liver was obtained in one case, and adjacent adenomatous lesions were collected in two cases. Seven tumors contained mutations in either the K-ras or p53 genes. In all cases, DNA derived from multiple sites within an individual tumor or metastatic deposits arising from that tumor showed the same pattern of gene mutation. Immunohistochemical staining for p53 protein overexpression also showed similar patterns of reactivity within individual tumors and their metastatic deposits. These results suggest that the major clonal expansion of colorectal carcinomas occurs after the acquisition of mutations in these genes. Our results also indicate that sampling errors are unlikely to occur in molecular studies aimed at defining the role of these genes in colorectal cancer progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634782     DOI: 10.1097/00019606-199512000-00006

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  6 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy.

Authors:  Satu Oltedal; Ole Gunnar Aasprong; Jannicke H Møller; Hartwig Kørner; Bjørnar Gilje; Kjersti Tjensvoll; Elke M Birkemeyer; Reino Heikkilä; Rune Smaaland; Oddmund Nordgård
Journal:  Int J Colorectal Dis       Date:  2011-05-15       Impact factor: 2.571

Review 3.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

4.  Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma.

Authors:  F Mayall; G Jacobson; R Wilkins; B Chang
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

5.  Heterogeneity of p53 mutational status in intramucosal carcinoma of the colorectum.

Authors:  S Yamada; Y Ajioka; H Watanabe; H Hashidate; H Takaku; S Kazama; J Yokoyama; K Nishikura; T Fujiwara; H Asakura
Journal:  Jpn J Cancer Res       Date:  2001-02

6.  Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.

Authors:  Sun Young Lee; Farhan Haq; Deokhoon Kim; Cui Jun; Hui-Jong Jo; Sung-Min Ahn; Won-Suk Lee
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.